ADMA Biologics (NASDAQ:ADMA) Announces Quarterly Earnings Results
ADMA Biologics (NASDAQ:ADMA) posted its earnings results on Wednesday. The biotechnology company reported ($0.19) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.23) by $0.04, Yahoo Finance reports. The company had revenue of $7.22 million for the quarter, compared to analyst estimates of $5.71 million. ADMA Biologics had a negative return on equity of 214.26% and a negative net margin of 323.54%.
ADMA Biologics stock traded down $0.24 during trading hours on Friday, hitting $4.28. The stock had a trading volume of 33,735 shares, compared to its average volume of 543,112. The company has a debt-to-equity ratio of 1.79, a current ratio of 10.26 and a quick ratio of 7.93. The stock has a market capitalization of $304.89 million, a price-to-earnings ratio of -2.95 and a beta of 2.70. ADMA Biologics has a 1-year low of $2.08 and a 1-year high of $6.31. The stock’s fifty day moving average is $4.61 and its two-hundred day moving average is $4.26.
Several analysts have weighed in on the company. Maxim Group set a $12.00 target price on ADMA Biologics and gave the company a “buy” rating in a report on Monday, October 21st. Dawson James lowered ADMA Biologics from a “buy” rating to a “neutral” rating and set a $4.00 target price on the stock. in a report on Monday, August 12th. BidaskClub raised ADMA Biologics from a “hold” rating to a “buy” rating in a report on Wednesday. Finally, ValuEngine raised ADMA Biologics from a “hold” rating to a “buy” rating in a report on Friday, September 20th. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average target price of $10.20.
ADMA Biologics, Inc, a biopharmaceutical and specialty immunoglobulin company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases. Its lead product candidate is RI-002 derived from human plasma, which has completed Phase III clinical trials for the treatment of primary immune deficiency disease.
Further Reading: Market Perform
Receive News & Ratings for ADMA Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ADMA Biologics and related companies with MarketBeat.com's FREE daily email newsletter.